• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
    • ATPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assay – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Novartis Uses Lipid Kinase Assay in a Quest for a PI4K Inhibitor

by Bellbrook Labs / Tuesday, 25 June 2019 / Published in HTS Assays, Success Stories
Lipid Kinase Assay PI4K Inhibitor

Did you know that diarrhea is the second leading cause of death globally among children under the age of 5?1 Perhaps you have heard of one of the many diarrheal diseases such as cryptosporidiosis caused by a parasite called Cryptosporidium. Many people in the US might associate swimming pools with outbreaks of cryptosporidiosis due to the parasite’s extreme chlorine tolerance. However, it’s a global issue that can be spread via water, food, animal-to-person, or person-to-person.2  Typically, the immune system rids the parasite from healthy individuals. This isn’t always the case, especially with immunocompromised groups. Luckily, a research team at Novartis invented a novel drug with the help of a lipid kinase assay, known as pyrazolopyridine KDU731 to treat cryptosporidiosis and its symptoms. 1,3

Why a PI4K Inhibitor?

After screening > 6000 drug candidates with established activity against an assortment of protozoan parasite, the researchers found the effects of pyrazolopyridines to be the most potent against Cryptosporidium.3 Pyrazolopyridines have many uses, including inhibition of lipid kinases; therefore, they are often investigated in targeting disease. Already knowing how similar drugs target other parasitic pathogens such as malaria, the researchers set out to determine the mechanism of their new drug candidate. Specifically, inhibition of the Plasmodium lipid kinase is the known target for antimalarial drugs. The next task was to identify a potential target kinase in Cryptosporidium that contributes to the drug’s success.3

A lipid kinase of the cryptosporidium protozoa, phosphatidylinositol – 4 – OH kinase (PI4K), was identified as being inhibited by a pyrazolopyridine that was developed into KDU731.3

Using a Lipid Kinase Assay for Further Development

The Novartis scientists that discovered the novel drug to fight cryptosporidiosis used the Transcreener® ADP² Kinase Assay for further lead development. The universal lipid kinase assay can be used to detect the activity of virtually any kinase, including PI4K. The assay measured the activity of the enzyme which transfers a phosphate from ATP to a substrate, forming ADP. The product can be measured by using a specific antibody and a fluorescent tracer. Enzyme tested with the potential new pyrazolopyridine drug had significantly less activity and could continue to be developed with SAR.

With the aid of the Bill & Melinda Gates Foundation, Novartis will continue development and research on pyrazolopyridine KDU731.4   According to Manjunatha et al., additional safety preclinical evaluation is ongoing to support the initiation of human clinical trials.3   Hopefully, success of the new therapeutic will lead to improved survival rates due to diarrheal disease in the same way that the rotavirus vaccine has done.

References

  1. DIAGANA et al. Patent Application , COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS Pub . No . : US 2019 / 0030009 A1, Pub . Date : Jan . 31 , 2019
  2. CDC. How Molecular Tracking and CryptoNet Can Help. 2004:1-2.
  3. Manjunatha UH, Vinayak S, Zambriski JA, et al. Europe PMC Funders Author Manuscripts A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis. 2017;546(7658):376-380. doi:10.1038/nature22337.A
  4. Novartis forms alliance to develop medicines for treating infectious diarrheal disease  
    Press Release February 14, 2018. Novartis.com
Tagged under: Lipid Kinase Assay, PI4K Activity Assay, Transcreener ADP Kinase Assay

What you can read next

Newly Patented Aurora A Kinase Inhibitor a Promising Contender for Cancer Treatment
New Transcreener cGAS Assay
BellBrook Labs Launches Transcreener cGAS Activity Assay to Accelerate Drug Discovery
Measuring Dissociation Rates and Residence Times for Kinase Inhibitors using a Jump Dilution Protocol

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • PARP1 as a Hero vs Villain

    Is PARP1 a Hero or Villain?

    Not counting histones, PARP1 [Poly(ADP-ribose) ...
  • Ongoing Puzzle of c-SRC in Cancer Treatment

    Advancements in The Ongoing Puzzle to Understand c-SRC

    Nearly a half-century ago, sequences from the R...
  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP